bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common StockBusiness Wire • 01/19/23
bluebird bio Provides Update on Commercial Launch Progress, Program Milestones and 2023 Financial Outlook Ahead of Company Presentation at 41st Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/09/23
bluebird bio Appoints Joseph Vittiglio, JD, as Chief Business and Legal OfficerBusiness Wire • 01/03/23
BLUE Stock Alert: What to Know as the FDA Lifts Hold on Bluebird Bio TreatmentInvestorPlace • 12/19/22
FDA Lifts Partial Clinical Hold for bluebird bio's Sickle Cell Disease (SCD) Studies for Patients Under the Age of 18Business Wire • 12/19/22
New Data from bluebird bio's Gene Therapies for Transfusion-Dependent Beta-Thalassemia and Sickle Cell Disease Presented at 64th ASH Annual MeetingBusiness Wire • 12/10/22